创建帐户忘记密码？
输入您的登录电子邮件地址，我们将发送重置说明。
电子邮件地址* 请输入您的电子邮件地址.取消重置检查您的购物车检查打印摘要警报：您购物车中的商品不再可用且已被删除。对于给您带来的不便，我们深表歉意。提醒：您的订单中包含库存短缺的商品。请说明您是否希望我们在商品有货时发货，还是等到所有商品都可以一起发货。分批发货是可以接受的。注意：库存数量为估计值，从现在到现在可能会发生变化处理您的订单时。
快速商品输入项目#Qty添加到购物车运输和处理估算邮政编码获取估算我们无法估算必须通过以下方式发货的订单的运费motorfreight。
请求报价提交此购物车以获取报价。您将收到一封确认电子邮件，我们的报价团队可能会与您联系。定价在提交时未锁定，可能会发生变化。
请求报价订单摘要项目 $0.00 运费和处理TBDEst。税TBD免税？总计 $0.00支票OutPrint 摘要关闭获取通知注册以在该商品重新有货时接收电子邮件。
通知我关闭成功！您将收到一封电子邮件当该商品重新有货时。
登录电子邮件地址密码登录忘记密码？创建帐户忘记密码？
输入您的登录电子邮件地址，我们将发送重置说明。
电子邮件地址* 请输入您的电子邮件地址.取消重置快速订购商品 #QtyItem #QtyItem #QtyItem #QtyItem #QtyItem #QtyItem #QtyItem #QtyItem #QtyItem #QtyMore 行添加到购物车排序方式排序或筛选搜索：ProductsVideosKnowledgebaseSearching... 1) { page--;运行搜索（页面）； } return false;\"><上一个Page 0 of 0>NextSortFilterClose添加到购物车-+添加到购物车购买数量并节省！注册即可收到免费目录！只需一分钟！只需填写下面的表格并单击\"获取我的目录”。通过 USPS 运送最多可能需要两到三周的时间。
如果您在美国境外，请查看我们功能齐全的交互式目录。
名字名字为必填项。姓氏姓氏职称（可选）公司（可选）街道地址地址 1 为必填项。公寓、套房等（可选）城市城市为必填项。请选择一个州。ALABAMA--ALALASKA--AKAMERICAN SOMA--ASARIZONA--AZARKANSAS --美洲武装部队（非加利福尼亚州）--欧盟、中东、非洲和加拿大武装部队--太平洋武装部队--阿加利福尼亚州--卡科洛拉多--康涅狄格州--CT特拉华州--哥伦比亚特区--密克罗尼西亚州DCFED--佛罗里达州--佛罗里达州--加瓜姆--古哈瓦伊--伊达荷--伊迪利诺伊--伊林迪亚纳--伊尼奥瓦--伊肯萨斯--克肯塔基--基路易斯安那--拉迈恩--梅马绍尔群岛--马里兰州--马萨诸塞州--马米奇根--明尼苏达--MN密西西比州--MS密苏里州--莫蒙塔纳--MTNEBRASKA--内内华达州--NV新罕布什尔州--NH新泽西州--NJ新墨西哥州--NM纽约--北卡罗来纳州--NC北达科他州--ND北马里亚纳群岛--MPOHIO--奥克拉荷马州--俄克拉何马州--奥彭西瓦尼亚--巴布多黎各--普罗德岛-- RISOUTH CAROLINA--SCSOUTH DAKOTA--SDTENNESSEE--TNTEXAS--TXUTAH--UTVERMONT--VTVIRGIN ISLANDS--VIVIRGINIA--VAWASHINGTON--WAWEST VIRGINIA--WVWISCONSIN--WIWYOMING--WY邮政编码是必需的。美国电子邮件您愿意吗想要接收促销电子邮件吗？请输入应出现在这两个数字之间的数字。571573获取我的目录1. INDICATIONS AND USAGE Menomune A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined, is indicated for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menomune A/C/Y/W-135 vaccine is approved for use in persons 2 years of age and older. Menomune A/C/Y/W-135 vaccine is not indicated for the prevention of meningitis caused by microorganisms other than N. meningitidis serogroups A, C, Y, and W-135. Menomune A/C/Y/W-135 vaccine is not indicated for treatment of meningococcal infections. 2. DOSAGE AND ADMINISTRATION . Administration The lyophilized vaccine should be a white or off-white color to a light beige color. The diluent used for reconstitution is a clear liquid. Using a suitable size syringe, withdraw the supplied diluent (0.6 mL for single-dose presentation and 6.0 mL for multidose presentation) and inject into the vial containing the lyophilized vaccine. Swirl the vial until the vaccine is thoroughly dissolved. When reconstituted, the vaccine should be a clear, colorless liquid. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exist, the vaccine should not be administered. Withdraw and administer a 0.5 mL dose of Menomune A/C/Y/W-135 vaccine by subcutaneous injection. Vaccine supplied in single dose vials should be used immediately after reconstitution. Vaccine supplied in multidose vials may be used for up to 35 days after reconstitution if stored at 2 to 8 C (35 to 46 F). [See How Supplied/Storage and Handling (16.2).] . Primary Immunization Primary immunization with Menomune A/C/Y/W-135 vaccine consists of a single 0.5mL dose administered subcutaneously. The preferred site of administration is the deltoid region. The ACIP (Advisory Committee on Immunization Practices) has specfic recommendations for use of meningococcal vaccines. (1) (2) (3) . Revaccination The ACIP has recommendations for revaccination against meningococcal disease for persons at high risk who were previously vaccinated with Menomune A/C/Y/W-135 vaccine. (1) (3) If Menomune A/C/Y/W-135 vaccine is used for revaccination, the dose is 0.5mL administered subcutaneously. 3. DOSAGE FORMS AND STRENGTHS Menomune A/C/Y/W-135 vaccine is supplied as a lyophilized vaccine, in a single dose or a multidose (10 dose) vial, with corresponding single dose or multidose vial of diluent. The lyophilized vaccine is reconstituted with the diluent [see Dosage and Administration (2.1)]. After reconstitution, each dose consists of a 0.5mL suspension for injection. See Description (11) for the complete listing of ingredients. 4. CONTRAINDICATIONS . Hypersensitivity Do not administer to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to Menomune A/C/Y/W-135 vaccine or any component of the vaccine [see Description (11)]. . Latex The stoppers to the vials of lyophilized vaccine and diluent contain dry natural latex rubber that may cause allergic reactions in latex sensitive persons. . Management of Acute Allergic Reactions Appropriate medical treatment must be available to manage possible anaphylactic reactions following administration of the vaccine. . Moderate or Severe Acute Illness To avoid diagnostic confusion between manifestations of an acute illness and possible vaccine adverse effects, vaccination with Menomune A/C/Y/W-135 vaccine should be postponed in persons with moderate or severe acute illness. (4) . Limitations of Vaccine Effectivness Menomune A/C/Y/W-135 vaccine may not protect all recipients. . Altered Immunocompetence Persons who are immunosuppressed, including persons receiving immunosuppressive therapy, may have a diminished immune response to Menomune A/C/Y/W-135 vaccine [see Drug Interactions(7)]. . Data from Clinical Studies Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in clinical practice. In three clinical trials primarily designed to assess the safety and immunogenicity of another vaccine, Menactra [Meningococcal (Groups A, C, Y, W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine], participants were randomized to receive Menactra or Menomune A/C/Y/W-135 vaccine, which was used as a control vaccine. In these three trials, 1519 children 2-10 years of age, 972 persons 11-18 years of age, and 1170 adults 18-55 years of age, respectively, received a dose of Menomune A/C/Y/W-135 vaccine. Overall, of the children 2-10 years of age who received Menactra or Menomune A/C/Y/W-135 vaccine, 68% were enrolled at US sites and 32% were enrolled at a Chilean site. The median ages of US and Chilean children were 6 and 5 years, respectively; 50.5% were males; and 92.0% were Caucasian. Among participants 11 55 years of age who received Menactra or Menomune A/C/Y/ W-135 vaccine, all were enrolled at US sites; 54.8% were female; 87.7% were Caucasian. Solicited local and systemic reactions were monitored daily for 7 days post-vaccination using a diary card. Information on serious adverse events was collected at interim clinic visits and by telephone interview conducted 6 months post-vaccination. At least 94% of participants from the three studies completed the 6-month follow-up. Serious Adverse Events Across the three studies, serious adverse events within 6-months following Menomune A/C/Y/W-135 vaccine were reported in 0.7% of 1519 children 2-10 years of age, 0.6% of 972 persons 11-18 years of age, and 1.7% of 1170 persons 18-55 years of age. Solicited Adverse Events1 The most commonly reported solicited adverse events in US children 2-10 years of age were injection site pain, irritability and diarrhea. (Table 1) The most commonly reported solicited adverse events in adolescents, ages 11 - 18 years, and adults, ages 18 - 55 years, were injection site pain, headache and fatigue. (Table 2) Table 1: Percentage of US participants 2-10 years of age reporting solicited adverse events within 7 days following administration of Menomune - A/C/Y/W-135 vaccine * N = The total number of participants with data. The N is for 1027 participants for all solicited events except fever (N=1019). Moderate: Discomforting, interfered with or limited usual arm movement, Severe: Disabling, child unable to move arm. Moderate: 1.0 2.0 inches; Severe: 2.0 inches. Oral equivalent temperature; Moderate: 38.4-39.4 C, Severe: 39.5 C. Moderate: Skipped 2 meals, Severe: skipped 3 meals. # Moderate: 2 episodes, Severe: 3 episodes. Moderate: 3-4 episodes, Severe: 5 episodes. Moderate: Interferes with normal activities, Severe: disabling, unwilling to engage in play or interaction with others. Moderate: 1-3 hours duration, Severe: 3 hours duration. These solicited adverse events were reported as present or absent only. Moderate: Decreased range of motion due to pain or discomfort, Severe: unable to move major joints because of pain. Table 2: Percentage of participants 11-55 years of age reporting solicited adverse events within 7 days following administration of Menomune - A/C/Y/W-135 vaccine * N=Total number of participants with data. Moderate: Discomforting, interfered with or limited usual arm movement, Severe: Disabling, unable to move arm. Moderate: 1.0 2.0 inches; Severe: 2.0 inches. Moderate: Interferes with normal activities, Severe: disabling, requires bed rest. Oral equivalent temperature. Study 1: Moderate: 38.5-39.4 C, Severe: 39.5 C. Study 2: Moderate 39.0-39.9 C, Severe: 40.0 C. # Moderate: 3-4 episodes, Severe: 5 episodes. Moderate: Skipped 2 meals, Severe: skipped 3 meals. Moderate: 2 episodes, Severe: 3 episodes. Moderate: discomforting enough to interfere with activities, Severe: disabling requires bed rest and analgesics. These solicited adverse events were reported as present or absent only. 1 Events in Table 1 and Table 2 were collected in the clinical trials under \"Solicited local and systemic reactions\". . Data from Post-Marketing Experience The following adverse events have been spontaneously reported during post-approval use of Menomune A/C/Y/W-135 vaccine since 1993 through November 2008. Because these events were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to Menomune A/C/Y/W-135 vaccine exposure. The following adverse events were included based on severity, frequency of reporting or the strength of causal association to Menomune A/C/Y/W-135 vaccine. Immune system disorders 7. DRUG INTERACTIONS Do not mix Menomune A/C/Y/W-135 vaccine with other vaccines in the same syringe or vial. Immunosuppressive therapies may reduce the immune response to Menomune A/C/Y/W-135 vaccine. No safety and immunogenicity data are available on the concomitant administration of Menomune A/C/Y/W-135 vaccine with other US licensed vaccines. 8. USE IN SPECIFIC POPULATIONS . Pregnancy Pregnancy Category C. Animal reproduction studies have not been conducted with Menomune A/C/Y/W-135 vaccine. It is also not known whether Menomune A/C/Y/W-135 vaccine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Menomune A/C/Y/W-135 vaccine should be given to a pregnant woman only if clearly needed. . Nursing Mothers It is not known whether Menomune A/C/Y/W-135 vaccine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Menomune A/C/Y/W-135 vaccine is administered to a nursing woman. . Pediatric Use Safety and effectiveness of Menomune A/C/Y/W-135 vaccine in children below the age of 2 years have not been established. During a meningococcal serogroup A epidemic in sub-Saharan Africa, children 3 months to 16 years of age were vaccinated with a high molecular weight serogroup A/C meningococcal polysaccharide vaccine. In case-control studies, after 1 year of observation, vaccine efficacy against meningococcal serogroup A disease was estimated to be 87% [(90% Confidence Interval (CI), 52% to 96%], overall. After 3 years, efficacy was estimated to be 67% (90% CI, 40% to 82%) among children who were 4-16 years of age at the time of vaccination and 8% (90% CI, -102% to 58%) among children who were 1-3 years of age at the time of vaccination. (5) The efficacy of a serogroup C meningococcal vaccine in infants and young children was evaluated in a placebo-controlled trial during a serogroup C epidemic in Brazil. Vaccine efficacy was estimated to be 12% (95% CI, -55% to 62%) among children 6 to 23 months of age and 55% (95% CI, -4% to 72%) among children 24 to 36 months of age. (6) Geriatric Use Clinical studies of Menomune - A/C/Y/W-135 vaccine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. 11. DESCRIPTION Menomune A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined, is a vaccine for subcutaneous injection. Menomune A/C/Y/W-135 vaccine consists of a sterile lyophilized preparation of the group-specific polysaccharide antigens from N meningitidis, Group A, Group C, Group Y and Group W-135. N meningitidis are cultivated with Mueller Hinton agar (7) and Watson Scherp (8) media. The purified polysaccharide is extracted from the N meningitidis cells and separated from the media by procedures which include centrifugation, detergent precipitation, alcohol precipitation, solvent or organic extraction and diafiltration. No preservative is added during manufacture. The diluent (0.6 mL) for the single dose presentation contains sterile, pyrogen-free distilled water without preservative. The diluent (6 mL) for the multi-dose presentation contains sterile, pyrogen-free distilled water and thimerosal, a mercury derivative, which is added as a preservative for the reconstituted vaccine. [See How Supplied/Storage and Handling (16).] After reconstitution with diluent the vaccine is a clear colorless liquid suspension. Each 0.5 mL dose contains 50 mcg of polysaccharide from each of serogroups A, C, Y and W-135. Reconstituted vaccine from a multi-dose vial also contains 25 mcg mercury per dose. Each dose of vaccine contains 2.5 mg to 5 mg of lactose added as a stabilizer. (9) Potency is evaluated by measuring the molecular size of each polysaccharide component using a column chromatography method as standardized by the US Food and Drug Administration (FDA) and the World Health Organization (WHO) (10) for Meningococcal Polysaccharide Vaccine. 12. CLINICAL PHARMACOLOGY . Mechanism of Action The presence of bactericidal anti-capsular meningococcal antibodies has been associated with protection from invasive meningococcal disease. (11) (12) Menomune A/C/Y/W-135 vaccine induces the production of bactericidal antibodies specific to the capsular polysaccharides of serogroups A, C, Y and W-135. . Carcinogenesis, mutagenesis, impairment of fertility Menomune A/C/Y/W-135 vaccine has not been evaluated for carcinogenic or mutagenic potential or impairment of fertility. 14. CLINICAL STUDIES Effectiveness of Menomune A/C/Y/W-135 vaccine was inferred by evaluating the proportion of children 2-10 years of age achieving a pre-specified level of serum bactericidal antibody and the proportion of persons 11-55 years of age achieving a 4-fold increase from baseline in serum bactericidal antibody, for each serogroup. Evidence for clinical efficacy against serogroup specific meningococcal disease in school-age children and adults has been obtained from historical field trials and observational studies with other high molecular weight polysaccharide vaccines containing meningococcal serogroup A and/or C components. (6) No studies have been conducted to evaluate the efficacy of meningococcal polysaccharide vaccines against disease due to serogroups Y and W-135. Menomune A/C/Y/W-135 vaccine was used as the control vaccine in three US, multi-center, clinical trials designed primarily to evaluate the immunogenicity and safety of Menactra vaccine in children (2 10 years old), adolescents (11 18 years old), and adults (18 55 years old), respectively. In these trials, participants in the control arm received a dose of Menomune A/C/Y/W-135 vaccine. Sera were obtained before and approximately 28 days after vaccination. The Serum Bactericidal Assay (SBA) used to test sera contained an exogenous complement source that was either human (SBA-H) or, when correlated to SBA-H, baby rabbit (SBA-BR). (13) Data on immune responses, as measured by SBA-H, following Menomune A/C/Y/W-135 vaccine in a subset of children 2 10 years old are presented in Table 3. Data on immune responses, as measured by SBA-BR, following Menomune A/C/Y/W-135 vaccine in adolescents and adults are presented in Table 4. Table 3: Bactericidal Antibody Responses* to Menomune-A/C/Y/W-135 vaccine 28 Days After Vaccination for Subsets of Participants Aged 2-3 and 4-10 Years N =50-53 Menomune A/C/Y/W-135 vaccine Aged 4-10 Years N =84 The study was designed to show the safety and immunogenicity of Menactra vaccine are non-inferior to that of Menomune A/C/Y/W-135 vaccine. The table shows the immune response in Menomune A/C/Y/W-135 vaccine participants from this study. * Serum Bactericidal Assay with an exogenous human complement (SBA-H) source. N = Number of subset participants with at least one valid serology result at Day 0 and Day 28. The 95% CI for the Geometric Mean Titer (GMT) was calculated based on an approximation to the normal distribution. In participants 2-3 years of age with undetectable pre-vaccination SBA titers (ie, 4 at Day 0), rates of seroconversion (defined as SBA titer 8 at Day 28) following Menomune-A/C/Y/W-135 vaccine were 55%, serogroup A (n=16/29); 30%, serogroup C (n=13/43); 57%, serogroup Y (n=17/30); 26%, serogroup W-135 (n=11/43). In participants 4-10 years of age with undetectable pre-vaccination SBA titers (ie, 4 at Day 0), rates of seroconversion (defined as SBA titer 8 at Day 28) following Menomune A/C/Y/W-135 vaccine were 48%, serogroup A (n=10/21); 38%, serogroup C (n=19/50); 84%, serogroup Y (n=38/45); 68%, serogroup W-135 (n=26/38). Table 4: Bactericidal Antibody Responses* to Menomune A/C/Y/W-135 Vaccine 28 Days After Vaccination for Participants Aged 11-18 and 18-55 Years N =423 Menomune A/C/Y/W-135 vaccine Aged 18-55 Years N =1098 Both studies (11-18 and 18-55 years of age) were designed to show the safety and immunogenicity of Menactra vaccine are non-inferior to that of Menomune A/C/Y/W-135 vaccine. The table shows the immune response in Menomune A/C/Y/W-135 vaccine participants from these studies. * Serum Bactericidal Assay with baby rabbit complement (SBA-BR). N = Number of participants with valid serology results at Day 0 and Day 28. The 95% CI for the GMT was calculated based on an approximation to the normal distribution. The proportion of subjects with a 4-fold rise from baseline in SBA-BR titer for N. meningitidis for each of the serogroups A, C, Y and W-135, 28 days following vaccination with Menomune A/C/Y/W-135 vaccine. In participants 11-18 years of age with undetectable pre-vaccination SBA titers (ie, 8 at Day 0), rates of seroconversion (defined as a 4-fold rise in Day 28 SBA titers) following Menomune-A/C/Y/W-135 vaccine were 100%, serogroup A (n=93/93); 99%, serogroup C (n=151/152); 100%, serogroup Y (n=47/47); 99%, serogroup W-135 (n=138/139). In participants 18-55 years of age with undetectable pre-vaccination SBA titers (ie, 8 at Day 0), rates of seroconversion (defined as a 4-fold rise in Day 28 SBA titers) following Menomune-A/C/Y/W-135 vaccine were 99%, serogroup A (n=143/144); 98%, serogroup C (n=297/304); 97%, serogroup Y (n=221/228); 99%, serogroup W-135 (n=325/328). 15. REFERENCES Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005;54 (No. RR - 7): 1-21. Centers for Disease Control and Prevention. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR 2007;56:794-5. Centers for Disease Control and Prevention. Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2-10 years at increased risk for invasive meningococcal disease. MMWR 2007;56:1265-6. Recommendations of the Advisory Committee on Immunization Practices (ACIP) General Recommendations on Immunization. MMWR 2006 December 01;55(RR15):1-48. Reingold AL, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 1985;No.8447:114-118. Granoff DM, et al. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5th ed. Philadelphia, PA: WB Saunders Company; 2008:399-434. Mueller H, et al. A protein-free medium for primary isolation of the gonococcus and meningococcus. Proc Soc Exp Biol Med 1941;48:330. Watson RG, et al. The specific hapten of group C (group II a) meningococcus. II. Chemical nature. J Immunol. 1958;81:337. Tiesjema RH, et al. Enhanced stability of meningococcal polysaccharide vaccines by using lactose as a menstruum for lyophilization. Bull WHO 1977;55:43-48. WHO Technical Report Series, 1981;No.658. M kel PH, et al. Evolution of conjugate vaccines. Expert Rev Vaccines 2002;1(3):399-410. Goldschneider I, et al. Human immunity to the meningococcus. I. The Role of Humoral Antibodies. J Exp Med 1969;129:1307-1326. Maslanka SE, et al. Standardization and a Multilaboratory Comparison of Neisseria meningitidis Serogroup A and C Serum Bactericidal Assays. Clin and Diag Lab Immunol 1997;156-167. . How Supplied One single dose vial of lyophilized vaccine, with one 0.6 mL vial of diluent (contains no preservative). NDC 49281-489-01. One 10 dose vial of lyophilized vaccine, with one 6.0 mL vial of diluent (contains preservative). NDC 49281-489-91. . Storage Store lyophilized vaccine, diluent, and reconstituted vaccine, when not in use, at 2 to 8 C (35 to 46 F). Do not freeze. Do not use after the expiration date shown on the vial labels of the lyophilized vaccine and diluent. Discard remainder of reconstituted vaccine from multidose vials within 35 days after reconstitution. Vaccine from single dose vials should be used immediately after reconstitution. 17. PATIENT COUNSELING INFORMATION Before administration of Menomune A/C/Y/W-135 vaccine, health-care providers should inform the patient, parent or guardian of the benefits and risks of the vaccine. The health-care provider should provide the Vaccine Information Statements which are required by the National Childhood Vaccine Injury Act of 1986 to be given with each immunization. Patients, parents, or guardians should be instructed to report adverse reactions to their health-care provider. Menomune - A/C/Y/W-135 COMBINED neisseria meningitidis group a polysaccharide antigen, a, neisseria meningitidis group c polysaccharide antigen, a, neisseria meningitidis group y polysaccharide antigen, a and neisseria meningitidis group w-135 polysaccharide antigen, a kit Menomune - A/C/Y/W-135 COMBINED neisseria meningitidis group a polysaccharide antigen, a, neisseria meningitidis group c polysaccharide antigen, a, neisseria meningitidis group y polysaccharide antigen, a and neisseria meningitidis group w-135 polysaccharide antigen, a injection Neisseria Meningitidis Group A Polysaccharide Antigen, A (Neisseria Meningitidis Antigen) Neisseria Meningitidis Antigen 50 ug in 0.5 mL Neisseria Meningitidis Group C Polysaccharide Antigen, A (Neisseria Meningitidis Antigen) Neisseria Meningitidis Antigen 50 ug in 0.5 mL Neisseria Meningitidis Group Y Polysaccharide Antigen, A (Neisseria Meningitidis Antigen) Neisseria Meningitidis Antigen 50 ug in 0.5 mL Neisseria Meningitidis Group W-135 Polysaccharide Antigen, A (Neisseria Meningitidis Antigen) Neisseria Meningitidis Antigen 50 ug in 0.5 mL Drugs.com Mobile Apps The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices. Explore Apps Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 2 Aug 2021), Cerner Multum (updated 3 Aug 2021), ASHP (updated 30 July 2021) and others.